Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Suma Krishnan also recently made the following trade(s):
- On Friday, December 13th, Suma Krishnan sold 25,000 shares of Krystal Biotech stock. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00.
Krystal Biotech Stock Up 1.1 %
Shares of Krystal Biotech stock opened at $179.38 on Friday. The firm has a market cap of $5.17 billion, a PE ratio of 59.99 and a beta of 0.87. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The business’s fifty day simple moving average is $163.50 and its 200-day simple moving average is $173.90.
Institutional Trading of Krystal Biotech
Several institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech during the third quarter worth $40,000. Huntington National Bank boosted its holdings in Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after acquiring an additional 283 shares during the period. GF Fund Management CO. LTD. acquired a new position in Krystal Biotech in the 4th quarter valued at about $95,000. KBC Group NV increased its stake in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after purchasing an additional 132 shares during the period. Finally, Covestor Ltd lifted its position in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after purchasing an additional 642 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on KRYS. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Chardan Capital boosted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $220.00.
Check Out Our Latest Analysis on KRYS
About Krystal Biotech
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Stories
- Five stocks we like better than Krystal Biotech
- What is diluted earnings per share (Diluted EPS)?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.